Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 754

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 7
Chunk 754
---

     – 
  
    Payments on loan payables 
     (70,000) 
     – 
  
    Net cash provided by financing activities 
     200,000  
     – 

    Net change in cash and cash equivalents 
     (41,159) 
     (64,467)

    Cash and cash equivalents, beginning of period 
     156,178  
     220,645 

    Cash and cash equivalents, end of period 
    $115,019  
    $156,178 

    Supplemental disclosure of cash flow information: 

    Cash paid for income taxes 
    $2,400  
    $2,400 
  
    Cash paid for interest on loan payable 
    $6,214  
    $– 

See accompanying notes to consolidated financial
statements.

 F-7 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023

Unless the context otherwise requires, references
to the “Company,” “Mosaic,” “we,” “our,” or “us” in this Annual Report on
Form 10-K (“Report”) refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries.

1.        Organization
and Business

Organization

Mosaic ImmunoEngineering, Inc. (the “Company,”
“Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March
24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the
treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms
to expand our pipeline based on a deep understanding of immunotherapies.

The Company has two inactive wholly owned subsidiaries:
Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions
Group, Inc.

Going Concern and Management’s Plans

The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern. At December 31, 2024, the Company had cash and cash equivalents
of $115,019 and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability
to raise capital to fund future operations. We anticipate